Skip main navigation

Home > Search Results

Main contents starts here

Search Results

1 - 20 of about 80

Total 80 documents found.

  •  
  • Product Portfolio
  • Our portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the teatment of hypertension. These four drugs are designated as "international strategic products" and we are focusing on managing their product lifecycles to strengthen sales on a global level.
  • P.T. Takeda Indonesia
  • PT. Takeda Indonesia was established on September 28 1971, engages in the pharmaceutical business both ethical and over the counter products. Ever Growing High Performing Pharmaceutical Company is our vision. Well trained and high skill employees always dedicate to provide high quality of products and services. In the principle of providing innovative products, we run business fully comply with laws and business ethic.
  • P.T. Takeda Indonesia
  • PT. Takeda Indonesia didirikan tanggal 28 September 1971 adalah perusahaan farmasi yang memproduksi obat etikal dan obat bebas dengan visi "Ever Growing High Performing Pharmaceutical Company". Kami memiliki sejumlah staf yang terlatih baik yang berdedikasi untuk menyediakan produk dan layanan yang unggul. Dalam menjalankan bisnis kami senantiasa memantuhi semua peraturan dan menjunjung tinggi etika bisnis.
  • ANNUALREPORT2009TakedaPharmaceuticalCompanyLimited Annual Report 2009 Our Contribution to Financial and Social Responsibility Editorial Policy Takeda integrates its annual report and CSR report into a single publication with a mind to give readers a complete understanding of how our business operations are guided by Takeda-ism and other elements of our corporate philosophy. Contributes to the Health of Individuals Takeda has been supplying pharmaceuticals for more than 220 years while never forgetting the importance of protecting and preserving life. Over the years, we have developed a strong commitment to the highest ethical standards and strong sense of mission. As our operations became global in scale, demands concerning corporate social responsibility (CSR) increased. We believe that developing superior pharmaceutical products in accordance with the principles of Takeda-ism is the essence of CSR for the Takeda Group. Due to this strong link between our business activities and CSR, since fiscal 2006, Take
  • ANNUALREPORT2008 Annual Report 2008 Our Contribution to Financial and Social Responsibility TakedaPharmaceuticalCompanyLimited Contributes to The Health of Individuals Worldwide 1 This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainties, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on. Precautions Regarding Forward-Looking Statements Takeda has issued an integrated Annual and CSR Report since fiscal 2006, in order to facilitate a comprehensive underst
  • 38 Leuprorelin Acetate Leuprorelin acetate is an LH-RH agonist with a sustained-release formulation whereby the result of the drug delivery system (DDS) was devoted. In March 2008, its sustained-release injectable formulation, available up to once every six months, was also approved in France. Leuprorelin acetate is marketed in around 80 countries worldwide and is considered a gold standard therapy for prostate cancer. For prostate cancer and endometriosis Brand Names: Leuplin (Japan), Enantone (Europe, Asia) Once-daily dosing with lansoprazole, a proton pump* inhibitor, provides fast symptom relief for gastric and duodenal ulcers, and achieves high healing rates. Lansoprazole is marketed in around 90 countries worldwide and is recognized as the top brand in major countries. * Proton pump: an enzyme that functions in the final stages of acid secretion in gastric parietal cells Lansoprazole For peptic ulcers Brand Names: Prevacid (United States, Asia), Ogast, Lansox, Agopton (Europe), Takepron (Japan, Asia) A
  • ANNUALREPORT2007 Annual Report 2007 Our Contribution to Financial and Social Responsibility TakedaPharmaceuticalCompanyLimited Contributes to The Health of Individuals Worldwide The image in the globe: the molecular representation of ramelteon (Rozerem ), insomnia medication This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainty, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on. Precautions Regarding Forward-Looking Statements Aiming to facilitate unde
  • 28 Products Aiming to become a good consumer partner in the self-medication age Alinamin V Alinamin V&V NEW Alinamin 7 Alinamin 7 GOLD Leuprorelin Acetate Drug delivery system (DDS) research has resulted in the formulation of leuprorelin acetate, an LH-RH agonist, in a sustained-release formulation for the treatment of prostate cancer, endometriosis, and others. The sustained-release injectable formulation is available of up to once every four months in the U.S. Leuprorelin acetate is marketed in around 80 countries worldwide, and is considered a gold standard therapy for prostate cancer. For prostate cancer and endometriosis Brand names:Leuplin (Japan) Lupron Depot (United States) Enantone/ Trenantone (Europe, Asia) Once-daily dosing with lansoprazole, a proton pump* inhibitor, provides fast symptom relief for gastric and duodenal ulcers, and achieves high healing rates. Lansoprazole is marketed in around 90 countries worldwide and is recognized as the top brand in major countries. Lansoprazole For peptic u
  • Takeda Settles a Lawsuit over Remuneration for Employee Invention Regarding an Anti-prostate Cancer and Anti-endometriosis Drug, Leuplin® September 4, 2007
  • September 4, 2007, Osaka, Japan --- Takeda Pharmaceutical Company Limited ("Takeda") announced today that, following the advisory by Judges, it has settled a lawsuit claiming remuneration for employee inventions, regarding formulation patents covering "the sustained release formulation of Leuprorelin acetate (marketed under the brand name of "Leuplin" in Japan)", a treatment for prostate cancer and endometriosis, originated by Takeda. That lawsuit was brought against Takeda before the Tokyo District Court in October 2004 and December 2005 by plaintiffs who alleged that they had inherited the right to claim remuneration of the employee inventions.
  • ANNUALREPORT2006 Annual Report 2006 Our Contribution to Financial and Social Responsibility *The contents of this annual report are written based on the information as of FY2005 (April 1, 2005 to March 31, 2006) with some activities in FY2006 being included. This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainty, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on. Precautions Regarding Forward-Looking Statements There is a recent tendency that a comprehe
  • Takeda Annual Report 200624 Providing long-awaited pharmaceutical products and high-quality information to people worldwide: this is Takeda's mission. Marketing I prescribe Rozerem (ramelteon) because it provides an alternative with an excellent safety profile for patients who suffer from insomnia and may be concerned with the addiction potential of other products. Although sleep is not a priority for some individuals, sleep is important because it makes up one third of an individual's life. For people to be in their optimal mental and physical health, it is important to honor sleep. Dr. Lundt has practiced psychiatry and addiction medicine for the past 18 years and is board certified in both of those areas. Leslie Lundt, M.D. (Id. U.S.A.) 25 "After Rozerem, I not only have life, I have me back again. And now it's more about all the moments that take my breath away. To me, that's living." Rashelle Gussner (Id. U.S.A.) Rashelle Gussner suffered with insomnia for five years. Previously an energetic woman, havi
  • CONTRIBUTESTOTHEHEALTHOFINDIVIDUALSWORLDWIDE ANNUAL R E P O R T 2005 Year ended March 31, 2005 Together with our corporate philosophy of Takeda-ism, our high ethical standards and strong sense of mission, developed over our 220-year history of knowing about the value of life, have become a vital part of our management today. TAKEDA-ISM We, the members of the Takeda Group, pledge to act with integrity at all times, especially when facing difficulties or challenges. "Integrity" refers to our compliance with the highest ethical standards, our fairness and honesty in conducting every activity, and our perseverance in pursuing the ideal forms for our operations and management. Through the demonstration of these qualities, we show our commitment to building trust and confidence in all the people around us, and our determination to continue to expand the business. These empower our progress in our global endeavors to fulfill our mission to "strive toward better health for individuals and progress in medicine by dev
  • Takeda's Marketing Division in Japan, Takeda's U.S. subsidiary Takeda Pharmaceuticals North America, Inc. (TPNA), and European marketing companies in France, the United Kingdom, Italy, Germany, Austria, and Switzerland all handle Takeda's ethical drugs. In fiscal 2004, consolidated net sales of ethical drugs increased 37.7 billion, or 4.3%, over the prior fiscal year to 914.8 billion. JAPAN FOR THE BENEFIT OF ALL HEALTHCARE PROFESSIONALS AND ALL PATIENTS Based on Takeda's management mission, the Company continues to pursue promotional activities in line with its commitment to providing "the best medicine and information to all healthcare professionals and all patients." In fiscal 2004, Takeda pursued further growth of its mainstay products, amid increasingly fierce competition in each therapeutic area, and the influence of revisions to National Health Insurance (NHI) drug prices, by continuing to deliver high-quality information through its promotional activities. These efforts paid off, with Takeda products
  • Contributes To The Health Of Individuals Worldwide annual repor t 2004 year ended March 31, 2004 We Strive Toward Better Health For Individuals And Progress In Medicine By Developing Superior Pharmaceutical Products. The Takeda Group contributes to the health of individuals and to the progress of medicine by applying all our assets, both fiscal and intellectual, concentrating on our pharmaceuticals business, creating superior pharmaceutical products and offering top-quality services. This is our mission and raison d'etre. FORWARD-LOOKING STATEMENTS This annual report contains forward-looking statements regarding the Company's plans, outlook, strategies and results for the future. All forward-looking statements are based on judgements derived from the information available to the Company at the time of publication. Certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this report. These risks and uncertainties include, but are not limit
  • 18 Our Product Lineup: Lansoprazole -For peptic ulcers Leuprolide Acetate -For prostate cancer and endometriosis Brand Names: Leuplin (Japan) Lupron Depot (United States) Enantone (Europe, Asia) Drug delivery system (DDS) research has resulted in the formulation of leuprolide acetate in sustained-release formulation for the treatment of prostate cancer and endometriosis. The sustained-release formulation, Lupron Depot, which is available in dosages of up to once every four months, contributes significantly to improving the quality of life of patients. Leuprolide acetate is marketed in over 70 countries and is considered a gold standard therapy for prostate cancer. Brand Names: Takepron (Japan, Asia) Prevacid (United States, Asia) Ogast, Lansox, Agopton (Europe) Once-daily dosing with lansoprazole, a proton pump* inhibitor (PPI) developed by Takeda, provides fast symptom relief for gastric and duodenal ulcers, and achieves high healing rates. Supported by this excellent profile, lansoprazole is marketed in ar

Pages:[1] [2] [3] [4]   Next

Page Top